The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.
The experimental use of psychedelic (LSD) psychotherapy.
Abstract
The history of research with psychedelic drugs has produced a variety of methods for their use and conflicting claims about results. First came the wave of excitement among experimentalists in the 1950s when it was claimed that lysergic acid diethylamide (LSD) could produce a model psychosis which might be useful in understanding schizophrenia. While this promise was fading, enthusiastic reports about the possibility of LSD as an aid to psychotherapy in the treatment of alcoholism and other psychiatric disorders appeared. All these approaches were represented in 1959 at the first international conference devoted entirely to LSD. 1 Since then, there have been at least five more published proceedings of such conferences on various aspects of psychedelic drugs. 2-6 The most recent conference on various means of producing states of consciousness was sponsored by the Menninger Foundation and the American Association of Humanistic Psychology on April 7 to 11, 1969, in
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The model employed in the current trial was most similar to “psychedelic-peak therapy” from the 1950s through 1970s (Sherwood et al., 1962; Hoffer, 1967; Pahnke et al., 1970; Grof et al., 1973a).”
From Individual experiences in four cancer patients following psilocybin-assisted psychotherapy (2018) · cites this paper as Pahnke et al., 1970
Citations
Cites
Implications of LSD and experimental mysticism
Pahnke, W. N., & Richards, W. A. (1966) · Journal of Religion and Health · doi:10.1007/bf01532646 · Cited by 252
Self-citationPlamenatz, J. (1965) · Cited by 230
Chromosomal damage in human leukocytes induced by lysergic acid diethylamide: (440272008-015)
Cohen, M. M., Marinello, M. J., & Back, N. (1967) · PsycEXTRA Dataset · doi:10.1037/e440272008-015 · Cited by 167
In Vivo and in Vitro Chromosomal Damage Induced by LSD-25
Cohen, M. M., Hirschhorn, K., & Frosch, W. A. (1967) · New England Journal of Medicine · doi:10.1056/nejm196711162772001 · Cited by 150
(1969) · PubMed · Cited by 150
Self-citationThe psychedelic mystical experience in the human encounter with death
Pahnke, W. N. (1969) · Harvard Theological Review · doi:10.1017/s0017816000027577 · Cited by 147
Self-citation(1969) · doi:10.1176/ajp.125.10.1352 · Cited by 106
A Clinical Study of LSD Treatment in Alcoholism
Ludwig, A. M., Levine, J., Stark, L. H., & Lazar, R. (1969) · American Journal of Psychiatry · doi:10.1176/ajp.126.1.59 · Cited by 95
Leukocytes of Humans Exposed to Lysergic Acid Diethylamide: Lack of Chromosomal Damage
Loughman, W. D., Sargent, T. W., & Israelstam, D. M. (1967) · Science · doi:10.1126/science.158.3800.508 · Cited by 92
Chromosome Damage Not Found in Leukocytes of Children Treated with LSD-25
Bender, L., Sankar, D. V. S., Irwin, S., & Egozcue, J. (1968) · Science · doi:10.1126/science.159.3816.749 · Cited by 67
Cited by
Nichols, D. E. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.011478 · Cited by 1,762
“With respect to treatment of dying cancer patients, this group found that about two-thirds of cancer patients who received LSD treatment had improved mood and reduced anxiety and fear of death (Pahnke et al., 1969, 1970b; Grof et al., 1973).”
BackgroundPsilocybin-assisted treatment for alcohol dependence: A proof-of-concept study
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A., Wilcox, C. E., Barbosa, P., & Strassman, R. J. (2015) · Journal of Psychopharmacology · doi:10.1177/0269881114565144 · Cited by 1,151
“Clinical work with classic hallucinogens has emphasized the central role of the altered state of consciousness experienced during the drug’s acute effects (Grof, 2008; Hoffer, 1967; Masters and Houston, 2000; Pahnke et al., 1970; Sherwood et al., 1962).”
Pilot study of the 5-HT 2A R agonist psilocybin in the treatment of tobacco addiction
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P., & Griffiths, R. R. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114548296 · Cited by 914
“This approach was informed by studies of hallucinogen-facilitated substance dependence treatment in which investigators described an extended, time-limited, postsession period (sometimes referred to as an “afterglow”) associated with decreased substance use, elevated mood and energy, decreased anxiety, and increased c…”
BackgroundRoseman, L., Nutt, D. J., & Carhart-Harris, R. L. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00974 · Cited by 808
“…can be predictive of subsequent psychological health, whether induced by psychedelics (O’Reilly and Funk, 1964; Klavetter and Mogar, 1967; Pahnke et al., 1970; Kurland et al., 1972; Richards et al., 1977; Maclean et al., 2011; Garcia-Romeu et al., 2014; Bogenschutz et al., 2015;…”
BackgroundMethodResultInfluentialGasser, P., Holstein, D., Michel, Y., Doblin, R., Yazar-Klosinski, B., Passie, T., & Brenneisen, R. (2014) · Journal of Nervous & Mental Disease · doi:10.1097/nmd.0000000000000113 · Cited by 750
“Congruent with earlier studies (Pahnke et al., 1970), the results in the experimental dose group show a significant reduction in state anxiety, as experienced on a daily basis.”
Result
Metadata
- Authors
- Pahnke, W. N.
- Affiliations
- Johns Hopkins University (US)
- Corresponding author
- Pahnke, Walter N.
- Venue
- JAMA: The Journal of the American Medical Association
- Publisher
- American Medical Association (AMA)
- Published
- 1970-06-15
- Volume
- 212
- Issue
- 11
- Pages
- 1856
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2006587749
- Cited by
- 220
- References
- 20
- Citations by year
- 2026: 9 · 2025: 19 · 2024: 21 · 2023: 17 · 2022: 16 · 2021: 22 · 2020: 12 · 2019: 6 · 2018: 18 · 2017: 10 · 2016: 7 · 2015: 6 · 2014: 8 · 2013: 5 · 2012: 4
- FWCI
- 7.46
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
- Social Sciences › Psychology › Clinical Psychology › Psychotherapy Techniques and Applications
- Social Sciences › Psychology › Social Psychology › Paranormal Experiences and Beliefs
- Keywords
- lysergic acid diethylamide, LSD, psychedelics, psychedelic therapy, alcoholism treatment, schizophrenia, states of consciousness, history of psychedelic research
- MeSH terms
- Alcoholism, Breast Neoplasms, Chromosome Aberrations, Depression, Female, Humans, Lysergic Acid Diethylamide, Middle Aged, Neoplasm Metastasis, Neurotic Disorders, Psychotherapy, Substance-Related Disorders
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The experimental use of psychedelic (LSD) psychotherapy. https://app.cochat.ai/papers/10.1001/jama.1970.03170240060010
- The paper
- Pahnke, W. N. (1970). The experimental use of psychedelic (LSD) psychotherapy. JAMA: The Journal of the American Medical Association. https://doi.org/10.1001/jama.1970.03170240060010
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.